gracecastuc-029_lung_drs. camidge & langer - repeat biopsy if not enough tissue for molec. testing?
Published 11 years ago • 30 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:15
gracecastuc-054_lung_wakelee: my approach to repeat biopsies for adv. nsclc with insufficient tissue
-
2:25
gracecastuc-075_lung_recommending a repeat biopsy with acqd. resistance to targeted therapy
-
3:32
gracecastuc100_lung_drs. camidge and langer on which patients send molecular marker testing
-
1:59:57
grace - global resource for advancing cancer education live stream
-
1:09
gracecastuc-037_lung_repeat biopsy at initial diag. or with acqd. resistance to a targeted therapy?
-
1:25
gracecastuc105_lung_dr. juergens on repeat biopsy acquired resistance
-
2:35
gracecastuc-028_lung_dr. goldberg - pros & cons of molecular testing with delays & rebiopsy
-
0:13
the importance of biomarker testing- targeted therapies in lung cancer 2023- #shorts #youtubeshorts
-
4:07
gracecastuc-064_lung_drs. camidge and langer: how should we manage acquired resistance?
-
4:42
grace targeted therapies in lung cancer 2021 - anxiety burden: wait for results, beginning treatment
-
3:58
gracecastuc-009_ca-101_do we need to do repeat biopsies with disease progression?
-
1:35
gracecastuc 130 lung_use of a broad molecular profile brought by a patient
-
2:32
segmentectomy for early stage nsclc - onctalk lung 2023
-
16:39
gracecast-067_lung-cancer_expert round table - nsclc molecular markers case 3
-
6:11
gracecastuc-012_lung_the more you seek, the more you find
-
35:02
gracecast-039_lung-cancer_pennell nsclc molecular markers webinar
-
8:46
grace targeted therapies in lung cancer 2021 - liquid and tissue biopsies in acquired resistance
-
4:06
gracecastuc090_lung_widespread availability of mutation testing
-
2:01
should we use dna or rna for ngs? - 2022 program: targeted therapies forum